Pd-C | 125620-28-2

• 英文名称: Pd-C
• CAS: 125620-28-2
• 化学式: CH₃Pd
• 分子量: 121.455
• InChiKey: SVXCWJLNVYZJNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.58
• 重原子数：
  2.0
• 可旋转键数：
  0.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  Pd-C 、 N-(4-phenylbutyryl)-L-proline benzyl ester 以 甲醇 、 氢气 为溶剂， 生成 N-(4-phenylbutanoyl)-L-proline
  参考文献：
  名称：

  Proline derivatives possessing prolyl endopeptidase-inhibitory activity

  摘要：

  以下是公式（I）的新脯氨酸衍生物：##STR1##其中每个符号如规范中定义的那样，这些衍生物特异性地抑制脯氨酸内切肽酶活性，可用于预防和/或治疗痴呆症和健忘症，作为直接作用于痴呆症中心症状的药物。

  公开号：

  US05506256A1
• 作为产物：
  描述：

  钯 、 methane 生成 Pd-C
  参考文献：
  名称：

  Laser vaporization generation of PdCH₃, ¹⁰⁵PdCH₃, and Pd¹³CH₃ for electron spin resonance neon matrix study at 4 K

  摘要：

  The Pd12CH3, Pd13CH3, and 105Pd12CH3 radicals have been generated by reactive laser vaporization and isolated in neon matrices at 4 K for electron spin resonance (ESR) investigation. Apparently no previous monomethyl metal radical has been characterized by ESR despite the importance of such species as reactive intermediates. These results allow an experimental description of the electronic structure in the valence region to be obtained. A direct electronic structure comparison between PdH and PdCH3 is also presented. A significant amount of s/d hybridization on Pd is observed which agrees with earlier calculations on the bonding in Pd(CH3)2. The magnetic parameters (MHz) for PdCH3 in neon matrices are: g⊥=2.273(1); for 105Pd, A⊥=−946(2), A∥=−987(20); for H, ‖A‖=13(1); and for 13C, ‖A‖=10.2(4).

  DOI：

  10.1063/1.458326
• 作为试剂：
  描述：

  2-(Benzylamino)-2-(6-(benzyloxy)-3,4-dihydronaphthalen-2-yl)propane-1,3-diol 在 Pd-C 、 对甲苯磺酸一水合物 、 trifluoroborane diethyl ether 、 碳酸氢钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 tert-Butyl 5-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-2,2-dimethyl-1,3-dioxan-5-ylcarbamate
  参考文献：
  名称：

  Heterobicyclic sphingosine 1-phosphate analogs

  摘要：

  提供具有在一个或多个S1P受体上拮抗活性的化合物。这些化合物是类似神经酰胺的类似物，在磷酸化后可以在S1P受体上表现为拮抗剂。

  公开号：

  US20140100195A1

文献信息

• Thiazolylbenzofuran derivatives and pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05994378A1

  公开（公告）日：1999-11-30

  This invention relates to novel thiazolylbenzofuran derivatives of formula (I) wherein R.sup.1 is lower alkyl, L is single bond or lower alkylene optionally substituted with aryl, oxo or hydroxy, and Q is a heterocyclic group optionally substituted with one or more suitable substituent(s); or lower alkoxy substituted with aryl which is substituted with one or more suitable substituent(s) and at least one of which is lower alkoxy optionally substituted with cyano, protected carboxy, carboxy, lower alkylene, a heterocyclic group optionally substituted with oxo, or amidino optionally substituted with hydroxy or lower alkoxy, or its salt, which possess activities as leukotriene and SRS-A antagonists or inhibitors.

  本发明涉及新颖的噻唑基苯并呋喃衍生物，其具有公式（I），其中R1是低级烷基，L是单键或可被芳基、氧基或羟基取代的低级亚烷基，Q是可被一个或多个适当取代基取代的杂环基；或者是被芳基取代的低级烷氧基，该芳基被一个或多个适当取代基取代，并且至少一个是可被氰基、受保护的羧基、羧基、低级亚烷基、可被氧基取代的杂环基或可被羟基或低级烷氧基取代的胍基取代的低级烷氧基，或其盐，其具有作为白三烯和SRS-A拮抗剂或抑制剂的作用。
• Piperidine derivatives
  申请人：Kowa Co., Ltd.

  公开号：US05714501A1

  公开（公告）日：1998-02-03

  A piperidine derivative of formula (1) or salts thereof: ##STR1## wherein R.sup.1 and R.sup.2 independently represent H or together represent O, R.sup.3 represents H, --R.sup.5 --COOR.sup.6, or --COOR.sup.6 (wherein R.sup.5 is a lower alkylene group, --CONH--, or --CONHCH.sub.2, and R.sup.6 is H or a lower alkyl group), R.sup.4 represents H, an aralkyloxy carbonyl group, an aminomethyl carbonyl group, or an aralkyloxy carbonyl aminomethyl carbonyl group, A represents O or a double bond, and the broken line has the meaning that a bonding hand may be present; and preventive and therapeutic agents for allergies, antihistaminic agents, and antileucotriene agents comprising the derivative or salts as their effective component. The compound of formula (1) has excellent antihistaminic activities and antileukotriene activities, which are well balanced, and is useful as a drug for the prevention and treatment of allergies such as asthma, allergic rhinitis, allergic dermatosis and urticaria.

  公式（1）的哒啶衍生物或其盐：##STR1##其中R.sup.1和R.sup.2独立地代表H或一起代表O，R.sup.3代表H，--R.sup.5--COOR.sup.6，或--COOR.sup.6（其中R.sup.5是较低的烷基烯基，--CONH--，或--CONHCH.sub.2，而R.sup.6是H或较低的烷基烯基），R.sup.4代表H，芳基氧羰基，氨甲基羰基，或芳基氧羰基氨甲基羰基，A代表O或双键，虚线表示键合手可能存在；以及包括该衍生物或其盐作为有效成分的过敏症预防和治疗剂，抗组胺剂和抗白三烯剂。公式（1）的化合物具有优异的抗组胺活性和抗白三烯活性，平衡性良好，并且可用作预防和治疗哮喘、过敏性鼻炎、过敏性皮肤病和荨麻疹等过敏症的药物。
• Methods of producing carboxylic acid ester derivatives and intermediates
  申请人：Fujirebio Inc.

  公开号：US05481009A1

  公开（公告）日：1996-01-02

  Methods of producing carboxylic acid ester derivatives of formulae (I) and (II), which are useful, for instance, as intermediates for producing an anti-hypercholesterolemic agent having an inhibitory effect on HMG-CoA Reductase: ##STR1## wherein R.sup.1 and R.sup.2 are independently a protective group for hydroxyl group, or R.sup.1 and R.sup.2 integrally constitute a protective group for hydroxyl groups; R.sup.3 is an alkyl group, or an aryl group; and R.sup.4 is a substituted aryl group, a substituted heterocyclic group, a substituted vinyl group, or a substituted cycloalkenyl group; and ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are respectively the same as defined in the above formula (I), are disclosed. In addition, intermediates for use in these methods of producing the carboxylic acid ester derivatives are disclosed.

  生产具有以下式(I)和(II)的羧酸酯衍生物的方法，例如，作为生产对HMG-CoA还原酶具有抑制作用的抗高胆固醇药物的中间体：##STR1## 其中R.sup.1和R.sup.2分别是羟基的保护基，或者R.sup.1和R.sup.2整体构成羟基的保护基；R.sup.3是烷基，或芳基；R.sup.4是取代芳基，取代杂环基，取代乙烯基，或取代环烯基；和##STR2## 其中R.sup.1，R.sup.2，R.sup.3和R.sup.4分别与上述式(I)中定义的相同，被揭示。此外，还揭示了用于这些生产羧酸酯衍生物的方法的中间体。
• Endothelin antagonists
  申请人：Abbott Laboratories

  公开号：US06162927A1

  公开（公告）日：2000-12-19

  A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

  公开了一种具有以下化学式（I）的化合物：##STR1##或其药用可接受的盐，以及制备该化合物的方法、中间体，以及一种拮抗内皮素的方法。
• Precursors for deoxyribonucleotides containing non-standard nucleosides
  申请人：——

  公开号：US06140496A1

  公开（公告）日：2000-10-31

  The disclosure describes building blocks for preparing oligonucleotides carrying non-standard nucleobases that can pair with complementary non-standard nucleobases so as to fit the Watson-Crick geometry, in that the resulting base pair joins a monocyclic six membered ring pairing with a fused bicyclic heterocyclic ring system composed of a five member ring fused with a six member ring, with the orientation of the heterocycles with respect to each other and with respect to the backbone chain analogous to that found in DNA and RNA, but with a pattern of hydrogen bonds holding the base pair together different from that found in the AT and GC base pairs (a "non-standard base pair").

  披露描述了用于准备携带非标准核碱基的寡核苷酸的构建模块，这些核碱基可以与互补的非标准核碱基配对，以适应沃森-克里克几何构型，即由结果碱基对连接的单环六元环与由五元环与六元环组成的融合双环杂环环系统配对，杂环的取向相对于彼此和相对于骨架链的类似于DNA和RNA中发现的取向，但通过一种不同于AT和GC碱基对中发现的氢键模式将碱基对保持在一起（“非标准碱基对”）。